CD274 and non-small cell lung carcinoma: Liu et al. (26) described a case of cT1cN2M0 NSCLC with programmed cell death-ligand 1 (PD-L1) expression of 90%, in which the patient received 2 months of dabrafenib plus trametinib before undergoing complete resection and exhibiting major pathological response (MPR).